1.19

0.84% 0.00

Actinium Pharmaceuticals Inc (ATNM)

Overview News Price History Option Chain Discussions Forecast Stock Split

Actinium Pharmaceuticals Inc stock is traded at $1.19, with a volume of 15,309. It is up +0.84% in the last 24 hours and up +11.11% over the past month. Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Previous Close:

$1.19

Open:

$1.19

24h Volume:

15,309

Relative Volume:

0.11

Market Cap:

$37.42M

Revenue:

$90,000

Net Income/Loss:

$-23.47M

P/E Ratio:

-1.582

EPS:

-0.7522

Net Cash Flow:

$-22.98M

1W Performance:

-1.64%

1M Performance:

+11.11%

6M Performance:

+11.11%

1Y Performance:

-24.53%

1-Day Range:

$1.18

$1.205

1-Week Range:

$1.16

$1.25

52-Week Range:

$0.7351

$1.74

Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile

Name

Actinium Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (595)

Phone

646-767-3870

Address

275 Madison Avenue, 7th Floor, New York, NY

Employee

Twitter

@actiniumpharma

Next Earnings Date

2026-11-13

Latest SEC Filings

ATNM's Discussions on Twitter

Compare ATNM vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATNM Actinium Pharmaceuticals Inc	1.1901	37.42M	90,000	-23.47M	-22.98M	-0.7522
VRTX Vertex Pharmaceuticals Inc	521.23	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.49	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	193.91	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	958.75	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.30	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-24	Downgrade	B. Riley Securities	Buy → Neutral
May-14-24	Initiated	Stephens	Overweight
Sep-06-23	Initiated	HSBC Securities	Buy
Feb-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-08-22	Initiated	Cantor Fitzgerald	Overweight
Aug-25-22	Initiated	B. Riley Securities	Buy
Nov-05-20	Initiated	Alliance Global Partners	Buy
Dec-06-17	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Resumed	ROTH Capital	Buy
Sep-14-17	Initiated	Maxim Group	Buy
Aug-25-16	Initiated	ROTH Capital	Buy
Feb-29-16	Initiated	H.C. Wainwright	Buy
Oct-15-15	Initiated	FBR Capital	Outperform
Oct-01-14	Initiated	MLV & Co	Buy
Jul-22-14	Initiated	Canaccord Genuity	Buy

View All

Actinium Pharmaceuticals Inc Stock (ATNM) Latest News

Sep 15, 2026

ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio - Yahoo Finance

Sep 15, 2026

Sep 04, 2026

Actinium CEO to present at H.C. Wainwright Glob... - Pluang

Sep 04, 2026

Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire

Sep 04, 2026

Actinium Pharmaceuticals (ATNM) grants director new stock awards - Stock Titan

Sep 04, 2026

Actinium Pharmaceuticals (ATNM) grants director $1.00 options and RSUs - stocktitan.net

Sep 04, 2026

Aug 23, 2026

Actinium (ATNM) Update: Slides 1.79% to $1.10 in Latest Trading; Next Test: Traders Can Monitor the $1.04-$1.16 Range in the Latest SessionBreakout Confirmation - vinanet.vn

Aug 23, 2026

Actinium (ATNM) Results Check: EPS Clears the Reported Estimate in the Latest Reading; After Earnings: Shares Move 1.79% Down for the Current SessionNegative Surprise Momentum - careplusvn.com

Aug 23, 2026

Aug 19, 2026

Actinium (ATNM) Chart: Ends Up by 3.24% at $1.11 in Latest Trading; Level Watch: the Supplied Trading Band Runs From $1.05 to $1.17Up Down Ratio - vinanet.vn

Aug 19, 2026

KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView

Aug 19, 2026

ETFs Investing in Actinium Pharmaceuticals, Inc. Stocks - TradingView

Aug 19, 2026

Aug 15, 2026

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail

Aug 15, 2026

Aug 14, 2026

Form 8K Actinium Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update - TradingView

Aug 14, 2026

Actinium Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Aug 14, 2026

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update - PR Newswire

Aug 14, 2026

Aug 12, 2026

Actinium Pharmaceuticals (ATNM) Institutional Ownership 2026 - MarketBeat

Aug 12, 2026

Aug 10, 2026

Actinium Pharmaceuticals (ATNM) Slips 3.4% to $0.77 as Key Support at $0.73 Comes into FocusRelative Volume - vinanet.vn

Aug 10, 2026

Aug 05, 2026

Actinium Pharmaceuticals (ATNM) Falls 7.5% to $0.75 as Selling Pressure IntensifiesGrowth ETF - dars.gov.et

Aug 05, 2026

Aug 03, 2026

Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. (ATNM) InvestorsLead Plaintiff Deadline on May 27, 2025 - The National Law Review

Aug 03, 2026

Aug 01, 2026

Actinium Pharmaceuticals, Inc. (Delaware) Revenue Breakdown – AMEX:ATNM - TradingView

Aug 01, 2026

Jul 28, 2026

Actinium Pharmaceuticals (ATNM) Hovers Near Support With Modest DeclineSuperTrend - careplusvn.com

Jul 28, 2026

Jul 27, 2026

Class Action Lawsuit Filed: Actinium Pharmaceuticals, Inc. (ATNM)Join by May 27, 2025Contact Levi & Korsinsky - The National Law Review

Jul 27, 2026

Jul 26, 2026